<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739971</url>
  </required_header>
  <id_info>
    <org_study_id>AGEs-brain</org_study_id>
    <nct_id>NCT02739971</nct_id>
  </id_info>
  <brief_title>the Effect of Advanced Glycation End Products (AGEs) on Brain and Cognition</brief_title>
  <official_title>Effect of a Diet Low in Advanced Glycation End Products (AGEs) on Brain and Cognitive Function in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hebrew University of Jerusalem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether dietary intake of pre-formed advanced
      glycation end products (AGEs) modulates brain function measured by MRI) and cognitive
      function measured by a thorough neuropsychological battery. In a 6 months randomized parallel
      study of adults above the age of 65, with mild cognitive impairment (MCI) and type 2
      diabetes. The investigators will compare two groups numbering 60 subjects each. Both groups
      will be advised on a diet appropriate for type 2 diabetes in the elderly by a nutritionist.
      In addition, the intervention group will be instructed on how to cook a low-AGE diet , with
      the aim of achieving a 40-50% lower AGE content, and they will be closely followed throughout
      the study to ensure compliance. Since diet is a modifiable lifestyle, diminishing AGEs
      consumption by cooking in lower temperatures (higher cooking temperatures being associated
      with higher AGE production) may be a simple non-invasive intervention which has potential of
      delaying or preventing cognitive decline which is associated with dementia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in global cognition and domain specific as reflected in a composite cognitive score at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Neuropsychological test battery to assess global cognition and specific domains (memory, executive function, attention, language)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in brain volume and perfusion assessed by Arterial spin labeling (ASL) perfusion MRI at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in blood biomarkers at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Blood tests for AGEs markers (carboxymethyl lysine, CML and Methylglyoxal, MG), inflammatory markers (CRP, IL-6), diabetes related markers (Glucose, Insulin, Hemoglobin A1c) and endothelial functioning markers (VCAM1)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in microbiome composition</measure>
    <time_frame>6 months</time_frame>
    <description>Microbiome composition will be analyzed using the 16S rRNA gene amplicon pyrosequencing</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Low AGEs diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In addition to nutritional instructions for type 2 diabetes, this arm will receive additional instructions on how to reduce AGEs in diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular diet (high AGEs)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nutritional instructions for type 2 diabetes</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Nutritional counseling to reduce AGEs content in diet</intervention_name>
    <description>in the intervention group, subjects will receive oral and written instructions on how to reduce AGEs in diet mainly by changing cooking methods</description>
    <arm_group_label>Low AGEs diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Nutritional instructions for type 2 diabetes</intervention_name>
    <description>all subjects will receive nutritional instructions for type 2 diabetes</description>
    <arm_group_label>Low AGEs diet</arm_group_label>
    <arm_group_label>Regular diet (high AGEs)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild cognitive impairment

          -  A member of Maccabi health services

          -  AGE consumption above average consumption

        Exclusion Criteria:

          -  Dementia, stroke or other major neuropsychiatric condition that, or its medications,
             might affect cognition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michal Schnaider Beeri, PhD</last_name>
    <role>Study Director</role>
    <affiliation>The joseph sagol neuroscience center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roni Lotan, M.Sc</last_name>
    <phone>972-3-5307262</phone>
    <email>Roni.loten@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Joseph Sagol Neuroscience center, Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roni Lotan</last_name>
      <phone>972-3-5407262</phone>
      <email>roni.loten@sheba.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, Yong A, Striker GE, Vlassara H. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010 Jun;110(6):911-16.e12. doi: 10.1016/j.jada.2010.03.018.</citation>
    <PMID>20497781</PMID>
  </reference>
  <reference>
    <citation>Cai W, Uribarri J, Zhu L, Chen X, Swamy S, Zhao Z, Grosjean F, Simonaro C, Kuchel GA, Schnaider-Beeri M, Woodward M, Striker GE, Vlassara H. Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4940-5. doi: 10.1073/pnas.1316013111. Epub 2014 Feb 24.</citation>
    <PMID>24567379</PMID>
  </reference>
  <reference>
    <citation>Lubitz I, Ricny J, Atrakchi-Baranes D, Shemesh C, Kravitz E, Liraz-Zaltsman S, Maksin-Matveev A, Cooper I, Leibowitz A, Uribarri J, Schmeidler J, Cai W, Kristofikova Z, Ripova D, LeRoith D, Schnaider-Beeri M. High dietary advanced glycation end products are associated with poorer spatial learning and accelerated AÎ² deposition in an Alzheimer mouse model. Aging Cell. 2016 Apr;15(2):309-16. doi: 10.1111/acel.12436. Epub 2016 Jan 19.</citation>
    <PMID>26781037</PMID>
  </reference>
  <reference>
    <citation>Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, Zhu L, Striker GE, Vlassara H. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care. 2011 Jul;34(7):1610-6. doi: 10.2337/dc11-0091.</citation>
    <PMID>21709297</PMID>
  </reference>
  <reference>
    <citation>Ravona-Springer R, Luo X, Schmeidler J, Wysocki M, Lesser G, Rapp M, Dahlman K, Grossman H, Haroutunian V, Schnaider Beeri M. Diabetes is associated with increased rate of cognitive decline in questionably demented elderly. Dement Geriatr Cogn Disord. 2010;29(1):68-74. doi: 10.1159/000265552. Epub 2010 Jan 30.</citation>
    <PMID>20130405</PMID>
  </reference>
  <reference>
    <citation>Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Arch Neurol. 2007 Apr;64(4):570-5.</citation>
    <PMID>17420320</PMID>
  </reference>
  <reference>
    <citation>Beeri MS, Moshier E, Schmeidler J, Godbold J, Uribarri J, Reddy S, Sano M, Grossman HT, Cai W, Vlassara H, Silverman JM. Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mech Ageing Dev. 2011 Nov-Dec;132(11-12):583-7. doi: 10.1016/j.mad.2011.10.007. Epub 2011 Nov 3.</citation>
    <PMID>22079406</PMID>
  </reference>
  <reference>
    <citation>West RK, Moshier E, Lubitz I, Schmeidler J, Godbold J, Cai W, Uribarri J, Vlassara H, Silverman JM, Beeri MS. Dietary advanced glycation end products are associated with decline in memory in young elderly. Mech Ageing Dev. 2014 Sep;140:10-2. doi: 10.1016/j.mad.2014.07.001. Epub 2014 Jul 15.</citation>
    <PMID>25037023</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2016</study_first_submitted>
  <study_first_submitted_qc>April 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>October 9, 2016</last_update_submitted>
  <last_update_submitted_qc>October 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Ramit Ravona Springer</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>MRI and blood tests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

